What's new in the treatment of metastatic kidney cancer? (Q36126876)

12 August 2017

1 reference

title

What's new in the treatment of metastatic kidney cancer? (English)

1 reference

12 August 2017

2

Cora N Sternberg

1 reference

12 August 2017

Andrea Mancuso

1

1 reference

12 August 2017

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

95

1 reference

12 August 2017

issue

9

1 reference

12 August 2017

page(s)

1171-1180

1 reference

12 August 2017

cites work

Focus on kidney cancer

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Novel therapies for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Direct activation of human CD8 cytotoxic T lymphocytes by interleukin-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Phase II trial of thalidomide in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

Gene therapy clinical trials worldwide 1989-2004-an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2005.05535.X

10.1111/J.1464-410X.2005.05535.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference